Trial Profile

A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ampreloxetine (Primary)
Indications Orthostatic hypotension
Focus Therapeutic Use
Sponsors Theravance Biopharma

Most Recent Events

22 Jul 2019 Results presented in the Theravance Biopharma media release.
22 Jul 2019 According to a Theravance Biopharma media release, data from this trial were presented at the 32nd European Neurology Congress.
18 Jun 2019 According to a Theravance Biopharma media release, data from this trial were presented at the 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com